Towerview LLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Towerview LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$4.99 - $8.96 $124,750 - $224,000	-25,000 Reduced 50.0%	25,000 $158,000
Q1 2022 May 05, 2022	SELL	$3.84 - $9.74 $326,400 - $827,900	-85,000 Reduced 62.96%	50,000 $415,000
Q2 2021 Jul 26, 2021	SELL	$7.82 - $9.23 $39,100 - $46,150	-5,000 Reduced 3.57%	135,000 $1.15 Million
Q1 2021 May 04, 2021	BUY	$8.44 - $12.66 $84,400 - $126,600	10,000 Added 7.69%	140,000 $1.24 Million
Q4 2020 Jan 25, 2021	BUY	$7.98 - $12.29 $79,800 - $122,899	10,000 Added 8.33%	130,000 $1.6 Million
Q3 2020 Nov 03, 2020	BUY	$7.96 - $12.42 $338,300 - $527,850	42,500 Added 54.84%	120,000 $977,000
Q2 2020 Aug 06, 2020	BUY	$5.4 - $13.37 $418,500 - $1.04 Million	77,500 New	77,500 $744,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Towerview LLC, based on Form 13F filings with the SEC.

Stay updated on Towerview LLC with notifications on news.